Inflammatory Mediators in Induced Sputum and Airway Hyperresponsiveness in Cough Variant Asthma during Long-Term Inhaled Corticosteroid Treatment

Table 1

Clinical characteristics of the three studied groups.

	CVA group (𝑁=28)	Asthma group (𝑁=23)	Control group (𝑁=22)
Sex (M : F)	28 (13 : 15)	23 (10 : 13)	22 (12 : 10)
Age (years)	42.96 ± 14.23	40.73 ± 11.41	38.76 ± 13.18
Total IgE (IU·mL^-1)	657.85 (24.00 ~ 2342.00)^a	593.74 (37.40 ~ 2592.00)^a	65.46 (17.34 ~ 153.00)
FEV1% predicted	93.76 ± 12.72	90.24 ± 15.11	102.12 ± 14.49
FEV1/FVC	82.67 ± 4.76	84.13 ± 6.92	89.21 ± 4.7
Leukocyte (10^9/L)	6.65 ± 1.78	7.06 ± 1.91	6.71 ± 1.72
Neutrophil (%)	56.85 ± 9.52	60.72 ± 9.47	57.39 ± 7.20
Eosinophil (%)	7.28 ± 2.46^a	6.86 ± 2.58^a	3.08 ± 1.91
Basophil (%)	0.092 ± 0.076	0.074 ± 0.062	0.088 ± 0.049
Monocytes (%)	6.29 ± 1.05	6.47 ± 1.90	6.51 ± 1.35
Lymphocytes (%)	29.55 ± 8.83	33.16 ± 14.27	27.86 ± 15.23
Atopy	12/16^a	10/13^a	0/22

^a𝑃<0.05 compared with controls.